Targeted cytolysins synergistically potentiate cytoplasmic delivery of gelonin immunotoxin

Molecular Cancer Therapeutics

Volumn 12, Issue 9, 2013, Pages 1774-1782

  Pirie, Christopher M ^a   Liu, David V ^b   Dane Wittrup, K ^a,b  

^a MASSACHUSETTS INSTITUTE OF TECHNOLOGY   (United States)

^b Massachusetts Institute of Technology Cambridge   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; CLOSTRIDIUM PERFRINGENS TOXIN; CYTOLYSIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; FIBRONECTIN; GELONIN; HYBRID PROTEIN; IMMUNOTOXIN; LISTERIOLYSIN O; MICRORNA; SMALL INTERFERING RNA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BINDING AFFINITY; CANCER INHIBITION; CONTROLLED STUDY; CYTOTOXICITY; DRUG DELIVERY SYSTEM; DRUG POTENTIATION; DRUG SPECIFICITY; ENDOCYTOSIS; ENDOSOME; HUMAN; HUMAN CELL; MACROMOLECULE; MOLECULARLY TARGETED THERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN ENGINEERING; PROTEIN TARGETING; RECEPTOR AFFINITY;

ANIMALS; APOPTOSIS; CARCINOEMBRYONIC ANTIGEN; CELL LINE, TUMOR; CYTOPLASM; CYTOTOXINS; DRUG SYNERGISM; ENDOSOMES; FIBRONECTINS; HUMANS; IMMUNOTOXINS; MICE; MOLECULAR TARGETED THERAPY; ORGAN SPECIFICITY; RECEPTOR, EPIDERMAL GROWTH FACTOR; RIBOSOME INACTIVATING PROTEINS, TYPE 1;

EID: 84884524144     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-12-1023     Document Type: Article

References (42)

1. Shim MS, Kwon YJ. Efficient and targeted delivery of siRNA in vivo. FEBS J 2010;277:4814-27.
2. Lares MR, Rossi JJ, Ouellet DL. RNAi and small interfering RNAs in human disease therapeutic applications. Trends Biotechnol 2010;28: 570-9.
3. Varkouhi AK, Scholte M, Storm G, Haisma HJ. Endosomal escape pathways for delivery of biologicals. J Control Release 2011;151: 220-8.
4. Nishikawa M, Hashida M, Takakura Y. Catalase delivery for inhibiting ROS-mediated tissue injury and tumor metastasis. Adv Drug Deliv Rev 2009;61:319-26.
5. Zhao M, Biswas A, Hu B, Joo K-I, Wang P, Gu Z, et al. Redoxresponsive nanocapsules for intracellular protein delivery. Biomaterials 2011;32:5223-30.
6. Paterson Y, Guirnalda PD, Wood LM. Listeria and Salmonella bacterial vectors of tumor-associated antigens for cancer immunotherapy. Semin Immunol 2010;22:183-9.
7. Foster S, Duvall CL, Crownover EF, Hoffman AS, Stayton PS. Intracellular delivery of a protein antigen with an endosomal-releasing polymer enhances CD8 T-cell production and prophylactic vaccine efficacy. Bioconjug Chem 2010;21:2205-12.
8. Stirpe F, Barbieri L. Ribosome-inactivating proteins up to date. FEBS Lett 1986;195:1-8.
9. Kelley VE, Bacha P, Pankewycz O, Nichols JC, Murphy JR, Strom TB. Interleukin 2-diphtheria toxin fusion protein can abolish cell-mediated immunity in vivo. Proc Natl Acad Sci U S A 1988;85:3980-4.
10. Bjorn MJ, Groetsema G, Scalapino L. Antibody-pseudomonas exotoxin A conjugates cytotoxic to human breast cancer cells in vitro. Cancer Res 1986;46:3262-7.
11. Seon BK. Specific killing of human T-leukemia cells by immunotoxins prepared with ricinAchain and monoclonal anti-human T-cell leukemia antibodies. Cancer Res 1984;44:259-64.
12. Wu M. Enhancement of immunotoxin activity using chemical and biological reagents. Br J Cancer 1997;75:1347-55.
13. WuYN, Gadina M, Tao-Cheng JH, Youle RJ. Retinoic acid disrupts the golgi apparatus and increases the cytosolic routing of specific protein toxins. J Cell Biol 1994;125:743-53.
14. Vitetta ES, Cushley W, Uhr JW. Synergy of ricin A chain-containing immunotoxins and ricin B chain-containing immunotoxins in in vitro killing of neoplastic human B cells. Proc Natl Acad Sci U S A 1983; 80:6332-5.
15. Greenfield L, Johnson VG, Youle RJ. Mutations in diphtheria toxin separate binding from entry and amplify immunotoxin selectivity. Science 1987;238:536-9.
16. Goldmacher VS, Blattler WA, Lambert JM, McIntyre G, Stewart J. Cytotoxicity of gelonin conjugated to targeting molecules: effects of weak amines, monensin, adenovirus, and adenoviral capsid proteins penton, hexon, and fiber. Mol Pharmacol 1989;36:818-22.
17. FitzGerald DJ, Trowbridge IS, Pastan I, Willingham MC. Enhancement of toxicity of antitransferrin receptor antibody-Pseudomonas exotoxin conjugates by adenovirus. Proc Natl Acad Sci U S A 1983;80:4134-8.
18. Schnupf P, Portnoy DA. Listeriolysin O: a phagosome-specific lysin. Microbes Infect 2007;9:1176-87.
19. Geoffroy C, Gaillard JL, Alouf JE, Berche P. Purification, characterization, and toxicity of the sulfhydryl-activated hemolysin listeriolysin O from Listeria monocytogenes. Infect Immun 1987;55:1641-6.
20. Sun X, Provoda C, Lee K-D. Enhanced in vivo gene expression mediated by listeriolysin O incorporated anionic LPDII: its utility in cytotoxic T lymphocyte-inducing DNA vaccine. J Control Release 2010;148:219-25.
21. Giles RV, Spiller DG, Grzybowski J, Clark RE, Nicklin P, Tidd DM. Selecting optimal oligonucleotide composition for maximal antisense effect following streptolysin O-mediated delivery into human leukaemia cells. Nucleic Acids Res 1998;26:1567-75.
22. Walev I, Bhakdi SC, Hofmann F, Djonder N, Valeva A, Aktories K, et al. Delivery of proteins into living cells by reversible membrane permeabilization with streptolysin-O. Proc Natl Acad Sci U S A 2001;98: 3185-90.
23. Provoda CJ, Stier EM, Lee K-D. Tumor cell killing enabled by listeriolysin O-liposome-mediated delivery of the protein toxin gelonin. J Biol Chem 2003;278:35102-8.
24. Kerr DE, Wu GY, Wu CH, Senter PD. Listeriolysin O potentiates immunotoxin and bleomycin cytotoxicity. Bioconjug Chem 1997;8: 781-4.
25. Bergelt S, Frost S, Lilie H. Listeriolysin O as cytotoxic component of an immunotoxin. Protein Sci 2009;18:1210-20.
26. Tweten RK. Cholesterol-dependent cytolysins, a family of versatile pore-forming toxins. Infect Immun 2005;73:6199-209.
27. Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD. Convergent potency of internalized gelonin immunotoxins across varied cell lines, antigens, and targeting moieties. J Biol Chem 2011;286:4165-72.
28. Yamaizumi M, Mekada E, Uchida T, Okada Y. One molecule of diphtheria toxin fragment A introduced into a cell can kill the cell. Cell 1978;15:245-50.
29. Yazdi PT, Murphy RM. Quantitative analysis of protein synthesis inhibition by transferrin-toxin conjugates. Cancer Res 1994;54: 6387-94.
30. Chou T-C, Talalay P. Analysis of combined drug effects: a new look at a very old problem. Trends Pharmacol Sci 1983;4:450-4.
31. Chou TC, Talalay P. Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27-55.
32. Bliss CI. The toxicity of poisons applied jointly. Ann Appl Biol 1939;26: 585-615.
33. Yan H, Zhang B, Li S, Zhao Q. A formal model for analyzing drug combination effects and its application in TNF-alpha-induced NFkappaB pathway. BMC Syst Biol 2010;4:50.
34. Webb J. Enzyme and metabolic inhibitors [Internet]. New York, NY: Academic Press; 1963. p. 55-79.
35. Xing Y, Smith AM, Agrawal A, Ruan G, Nie S. Molecular profiling of single cancer cells and clinical tissue specimens with semiconductor quantum dots. Int J Nanomedicine 2006;1:473-81.
36. Mayor S, Pagano RE. Pathways of clathrin-independent endocytosis. Nat Rev Mol Cell Biol 2007;8:603-12.
37. Adler J, Parmryd I. Quantifying colocalization by correlation: the Pearson correlation coefficient is superior to the Mander's overlap coefficient. Cytometry A 2010;77:733-42.
38. Jones S, Portnoy DA. Characterization of Listeria monocytogenes pathogenesis in a strain expressing perfringolysin O in place of listeriolysin O. Infect Immun 1994;62:5608-13.
39. Lin Y, Shih WJ. Statistical properties of the traditional algorithmbased designs for phase I cancer clinical trials. Biostatistics 2001; 2:203-15.
40. Barrett JS, Wagner JG, Fisher SJ, Wahl RL. Effect of intraperitoneal injection volumeand antibody protein dose on the pharmacokinetics of intraperitoneally administered IgG2a kappa murine monoclonal antibody in the rat. Cancer Res 1991;51:3434-44.
41. Carrero JA, Vivanco-Cid H, Unanue ER. ListeriolysinO is strongly immunogenic independently of its cytotoxic activity. PLoS ONE 2012;7:e32310.
42. Onda M, Beers R, Xiang L, Lee B, Weldon JE, Kreitman RJ, et al. Recombinant immunotoxin against B-cell malignancies with no immunogenicity in mice by removal of B-cell epitopes. Proc Natl Acad Sci U S A 2011;108:5742-